---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-020615"
form_type: "8-K"
ticker: "GOVX"
cik: "0000832489"
company_name: "GeoVax Labs, Inc."
filed_at: "2024-06-18T23:59:59+00:00"
generated_at: "2026-06-01T04:00:37.673579+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# GeoVax receives BARDA award up to $45M for Phase 2b COVID-19 vaccine trial

## Summary
- Direct award to GeoVax of ~$24.3M, potentially increasing to $45M, for manufacturing and clinical trial support.
- BARDA separately commits ~$343M from Project NextGen for a CRO to execute the 10,000-participant Phase 2b study.
- Phase 2b double-blinded trial will compare GeoVax's GEO-CM04S1 against an FDA-approved mRNA COVID-19 vaccine.
- Study is part of HHS Project NextGen, a $5B initiative for next-generation COVID-19 vaccines and therapeutics.
- GeoVax's dual-antigen vaccine candidate aims to induce durable antibody and T-cell immunity against variants.

## SEC filing metadata
- accession: 0001437749-24-020615
- form_type: 8-K
- ticker: GOVX
- cik: 0000832489
- company_name: GeoVax Labs, Inc.
- filed_at: 2024-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/832489/000143774924020615/0001437749-24-020615-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/832489/000143774924020615/govx20240618_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-020615
- JSON: https://secwatch.observer/filing/0001437749-24-020615.json
- Plain text: https://secwatch.observer/filing/0001437749-24-020615.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.